**S1 Table. Assay sera dilutions**

|  |  |  |  |
| --- | --- | --- | --- |
| Assay | Sera dilution 1 | Sera dilution 2 | Sera dilution 3 |
| *Pf*DBL5a – IgG1 | 1/100 | 1/800 |  |
| *Pf*DBL5a – IgG3 | 1/100 | 1/800 |  |
| *Pf*MSP2b - IgG1 | 1/300 | 1/1,200 |  |
| *Pf*MSP2b - IgG3 | 1/1,000 | 1/4,000 | 1/10,000 |
| *Pf*AMA1c - IgG1 | 1/250 | 1/2,000 | 1/16,000 |
| *Pf*AMA1c - IgG3 | 1/250 | 1/1,000 | 1/4,000 |
| *Pf*EBA175RIId - IgG1 | 1/2,000 | 1/8,000 | 1/20,000 |
| *Pf*EBA175RIId – IgG3 | 1/1,000 | 1/4,000 | 1/10,000 |
| Measlese – IgG1 | 1/200 |  |  |
| Measlese – IgG3 | 1/200 |  |  |
| Total Sera IgG | 1/600,000 |  |  |

In all assays secondary (Ms anti-human IgG/IgG1/IgG3, Invitrogen) and tertiary (Goat anti-mouse HRP conjugated, Invitrogen) antibodies were diluted to 1/1000.

aAvril, M. et al. Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect. Immun. 78, 2248–2256 (2010).

bStanisic, D. I. et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 77, 1165– 1174 (2009).

cHodder, A. N., Crewther, P. E. & Anders, R. F. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69, 3286–3294 (2001).

dRichards, J. S. et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J. Immunol. 191, 795–809 (2013).

ePROSPECbio